This page provides information and guidance on lung cancer for health care professionals.
Information for patients can be found on our patient hub.
If would like further information on the Lung CSG please click here to contact us.
The National Optimal Pathway for lung cancer was developed in conjunction with the lung CSG to support the implementation of the the Single Cancer Pathway (SCP) in Wales.
The Welsh Thoracic Oncology Group (WTOG) has revised the Lung Cancer National Optimal Pathway (NOPLC). This second edition (2022) of the NOLCP reflects the changing developments in the treatment of lung cancer since the NOLCP was first described. A standardised approach to molecular and genetic testing of biopsies allows patients with both early and advanced stage lung cancer to benefit from an increasing range of novel therapies and improve access to clinical trials.
Contact details can be accessed via the NHS Wales Global address list. If you do not have access to this please click here to contact us.
| Health Board/MDT | MDT Lead | MDT Frequency |
| Aneurin Bevan UHB | Dr Mat Jones |
Thursdays 11:30 am Weekly |
| Betsi Cadwaladr UHB – Ysbyty Glan Clwyd | Dr Sakkarai Ambalavanan |
Wednesdays 11am Weekly |
| Betsi Cadwaladr UHB – Ysbyty Gwynedd | Dr Ali Thahseen |
Tuesdays 1pm Weekly |
| Betsi Cadwaladr UHB – Ysbyty Wrexham Maelor | Chair is shared by the team |
Wednesdays 8am Weekly |
| Cardiff & Vale UHB | Dr Diane Parry |
Thursdays 12:15pm Weekly |
| Cwm Taf UHB – Prince Charles | Dr Alex Jones |
Wednesdays 8:30am Weekly |
| Cwm Taf UHB – Princess of Wales | Dr Emma Watkins |
Thursdays 8:30pm Weekly |
| Cwm Taf UHB – Royal Glamorgan | Dr Sinan Eccles |
Tuesdays 8:30am Weekly |
| Hywel Dda UHB | Dr Gareth Collier |
Thursdays 1pm Weekly |
| Swansea Bay UHB | Dr Emrys Evans |
Mondays 9:30am Weekly |
The Welsh Thoracic Oncology Group Meeting 2022 took place on 1st October 2021. To access the recording please click here to contact us.
Wales Pleural Lead: Dr Alina Ionescu, Aneurin Bevan University Health Board
Mesothelioma Pathology Lead: Professor Richard Attanoos, Cardiff and Vale University Health Board
Mesothelioma is a rare form of cancer that occurs mainly in the lining of the lung (pleura). It can also occur in the lining of the abdomen, and heart. Mesothelioma is often linked to asbestos exposure.
Symptoms of Mesothelioma may include chest pain, shortness of breath, coughing, fatigue and weight loss.
Due to its aggressive nature and the difficulty of diagnosing it early, mesothelioma can be challenging to treat. As this is a rare form of cancer, a multidisciplinary approach to the diagnosis, support, treatment and management of symptoms is recommended.
Role of Welsh Mesothelioma MDT
The Welsh Mesothelioma MDT aims to support the diagnosis and management plan of patients with a confirmed new diagnosis of mesothelioma. Where there is a challenging diagnostic or therapeutic decision to be made, a secondary disciplinary discussion can be provided.
The MDT approach supports:
Refer to the Mesothelioma MDT
Mesothelioma Referrals forms are available here.
The Welsh Mesothelioma MDT is held weekly on Thursday at 12:00 (Video Conferencing Links are available by contacting the Mesothelioma MDT Co-ordinator).
The deadline for patients to be added to the MDT list for discussion is 12:00pm Monday.
Please ensure:
Although the meeting is hosted by Cardiff and Vale UHB, any clinicians within Wales involved in the diagnosis and treatment of patients with Mesothelioma are welcomed to join on a virtual basis. The meeting is attended by Respiratory Consultants, Thoracic Surgeons, Mesothelioma Clinical Nurse Specialists, Thoracic Radiologists, Thoracic Oncologists and Palliative Care Consultants.
Contact Details
Cardiff and Vale MDT Lead:
Dr Craig Dyer, Respiratory Consultant, Craig.Dyer@wales.nhs.uk
Mesothelioma MDT Co-ordinator:
Mesothelioma.MDT.CAV@wales.nhs.uk
Cardiff and Vale Lung Cancer CNS Team:
Wales Mesothelioma Clinical Nurse Specialist:
Rebecca Weston-Thomas: Rebecca.Weston-Thomas@wales.nhs.uk